Cancer of the nasal cavity and paranasal sinuses: a series of 115 patients.
V Svane-Knudsen, K E Jørgensen, O Hansen...
https://pubmed.ncbi.nlm.nih.gov/9569435Actively Recruiting
Led by Hongmeng Yu · Updated on 2024-02-13
25
Participants Needed
1
Research Sites
156 weeks
Total Duration
Researchers are evaluating the effectiveness of induction chemotherapy in patients with olfactory neuroblastoma, a rare type of cancer. The study aims to determine whether patients with different pathological subtypes benefit from different chemotherapy regimens. This prospective phase 2 clinical trial focuses on tumor remission rates and long-term survival outcomes based on molecular profiles of the tumor. Participants receive induction chemotherapy tailored to the molecular subtype of their tumor. Those with a Ki-67 index of 25% or higher are treated with a combination of gemcitabine and platinum-based drugs over two weeks. Patients with a Ki-67 index below 25% receive a different chemotherapy regimen consisting of cyclophosphamide, etoposide, and cisplatin. Additional drugs may be considered depending on disease progression. During the study, participants are monitored for tumor remission using objective remission rate measurements between 3 and 12 weeks after chemotherapy. Other assessments include pathological remission after surgery, surgical margin status, and treatment-related side effects over a two-year period. Overall survival is also tracked for two years to evaluate long-term outcomes. Participants will undergo regular follow-up visits to assess these outcomes and ensure safety.
CONDITIONS
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 weeks
Participants receive induction chemotherapy based on their tumor's molecular profile: those with a Ki-67 index ≥ 25% receive gemcitabine plus cisplatin, while those with a Ki-67 index < 25% receive cyclophosphamide, etoposide, and cisplatin. Treatment duration varies according to regimen and disease progression.
1 to 2 visits during chemotherapy
Duration - About 4 weeks up to 12 weeks
After induction chemotherapy, participants undergo surgical resection followed by pathological assessment to evaluate remission and surgical margin status.
1 visit (surgical and pathological evaluation)
Duration - 2 years (24 months)
Participants are monitored for overall survival and treatment-related side effects for up to 2 years after treatment completion.
Periodic visits for safety and survival assessments
Total: 1 location
1
Eye & ENT Hospital of Fudan University
Shanghai, Shanghai Municipality, China, 200031
Actively Recruiting
X
Xiaole Song, MD
J
Jingyi Yang, MD
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
V Svane-Knudsen, K E Jørgensen, O Hansen...
https://pubmed.ncbi.nlm.nih.gov/9569435Nalee Kim, Chang Geol Lee, Eui Hyun Kim...
https://pubmed.ncbi.nlm.nih.gov/30506150P Dulguerov, A S Allal, T C Calcaterra
https://pubmed.ncbi.nlm.nih.gov/11902539Marion Classe, Hui Yao, Roger Mouawad...
https://pubmed.ncbi.nlm.nih.gov/30332658